- Conditions
- Influenza A Virus Infection, Swine Flu
- Interventions
- Plasma collection following infection or vaccination with influenza A
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 60 Years · Male only
- Enrollment
- 102 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2018
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Influenza A, Influenza B
- Interventions
- Anti-Influenza Immune Plasma, Standard Care
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 35
- States / cities
- Los Angeles, California • San Diego, California • Torrance, California + 22 more
- Conditions
- Influenza A Virus Infection
- Interventions
- High-titer anti-influenza plasma, Low-titer anti-influenza plasma
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Weeks and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 30
- States / cities
- Tucson, Arizona • Los Angeles, California • San Diego, California + 23 more
- Conditions
- Infectious Diseases, Influenza, Avian Flu
- Interventions
- H5N1 vaccine, Apheresis
- Biological · Procedure
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Community-acquired Pneumonia, Influenza, COVID-19
- Interventions
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
- Drug · Other · Biological + 1 more
- Lead sponsor
- UMC Utrecht
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 11
- States / cities
- Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Influenza A Virus Infection
- Interventions
- Collection of Anti-Influenza A Immune Plasma
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 59 Years · Male only
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2019
- U.S. locations
- 2
- States / cities
- San Diego, California • Bethesda, Maryland
- Conditions
- AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
- Interventions
- Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
- Drug · Procedure · Other
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- 18 Years to 66 Years
- Enrollment
- 358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more